• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Prometheus Biosciences Inc.

    6/27/23 3:06:42 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RXDX alert in real time by email
    15-12G 1 eh230374429_1512g.htm FORM 15-12G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
    SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934.

      

    Commission File Number:      001-40187

     

    PROMETHEUS BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)
     

    3050 Science Park Road

    San Diego, California 92121

    (858) 422-4300

    (Address, including zip code, and telephone number,

    including area code, of registrant’s principal executive offices)

     

    Common Stock, $0.0001 par value per share

    (Title of each class of securities covered by this Form)
     
    None

    (Titles of all other classes of securities for which

    a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1)  ☒
      Rule 12g-4(a)(2)  ☐
      Rule 12h-3(b)(1)(i)  ☒
      Rule 12h-3(b)(1)(ii)  ☐
      Rule 15d-6  ☐
      Rule 15d-22(b) ☐

     

    Approximate number of holders of record as of the certification or notice date: 1

     

     

       

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Prometheus Biosciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    Date: June 27, 2023 PROMETHEUS BIOSCIENCES, INC.  
           
    By: /s/ Kelly E.W. Grez  
      Name: Kelly E.W. Grez  
      Title: Secretary  

     

     

     

     

       

     

    Get the next $RXDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RXDX

    DatePrice TargetRatingAnalyst
    5/10/2023$160.00 → $200.00Buy → Hold
    Jefferies
    7/20/2022$51.00Buy
    Goldman
    6/10/2022$53.00Overweight
    Piper Sandler
    3/10/2022$50.00 → $52.00Outperform
    Credit Suisse
    3/10/2022$42.00 → $53.00Overweight
    Wells Fargo
    3/10/2022$47.00 → $55.00Outperform
    SVB Leerink
    2/11/2022$62.00Buy
    BTIG
    12/13/2021$46.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $RXDX
    SEC Filings

    View All

    SEC Form 15-12G filed by Prometheus Biosciences Inc.

    15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)

    6/27/23 3:06:42 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Prometheus Biosciences Inc.

    25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)

    6/16/23 9:13:06 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Prometheus Biosciences Inc.

    S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)

    6/16/23 9:12:56 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RXDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellino Appoints Chris Gibson to Board of Directors

    Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

    10/24/24 8:00:00 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Completes Acquisition of Prometheus Biosciences, Inc.

    Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth

    6/16/23 4:04:00 PM ET
    $MRK
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

    SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th

    5/9/23 4:00:00 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prometheus Biosciences downgraded by Jefferies with a new price target

    Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously

    5/10/23 6:31:59 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Prometheus Biosciences with a new price target

    Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00

    7/20/22 7:36:43 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Prometheus Biosciences with a new price target

    Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00

    6/10/22 7:19:39 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mckenna Mark C.

    4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

    6/16/23 4:00:25 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Stenhouse Mark

    4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

    6/16/23 4:00:32 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hendrix Martin

    4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

    6/16/23 4:00:40 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care